# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Gilda Radner (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML026-SYN-TD
- Date: 1986-07-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Delia Marchand, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Review at the midpoint of chemotherapy, on the day of cycle 4. **S**

## History of present illness

Ms. Radner returns on the day of her fourth cycle of carboplatin and paclitaxel. Cycles 2 and 3 were given on schedule. The cold she had a week after cycle 2 cleared in five days without a fever. Nausea lasts a day or two after each cycle and is controlled with ondansetron, which she uses two or three times per cycle. For about two weeks she has had tingling in her toes and fingertips that does not stop her buttoning clothes, walking, or writing. Her hair has fallen out and she wears a scarf. Hot flashes continue. She goes to her support group every other week. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Treatment | Cycle 4 of 6 today; cycles 2 and 3 on schedule |
| Nausea | One or two days after each cycle; ondansetron two or three times |
| Neuropathy | Tingling in the toes and fingertips for two weeks; no effect on function |
| Infection | Cold after cycle 2 resolved without fever |
| Mood | PHQ-9 4; support group every other week |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired for a few days after each cycle; no fever |
| Gastrointestinal | Positive | Nausea for one or two days after each cycle; no vomiting; bowels regular |
| Neurological | Positive | Tingling in the toes and fingertips; no weakness or falls |
| Integumentary | Positive | Hair loss |
| Endocrine | Positive | Hot flashes |
| Respiratory | Negative | Cough gone; no breathlessness |
| Psychiatric | Negative | Mood steady; no thoughts of self-harm |

7 systems reviewed. **S**

## Current medications

- Carboplatin 10 mg/mL injection, 610 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cycles **S**
- Paclitaxel 6 mg/mL injection, 275 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidine **S**
- Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea **S**

## Allergies

- No known allergy **S**

## Objective

BP 110/70 mmHg; pulse 80 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 55.9 kg; BMI 21.8 kg/m². All vital signs are synthetic.

Hemoglobin: 10.3 g/dL (low); White cell count: 4.1 10*3/uL; Absolute neutrophil count: 1.9 10*3/uL; Platelets: 188 10*3/uL; Creatinine: 0.7 mg/dL; eGFR: 113 mL/min/1.73 m²; ALT: 24 U/L; Total bilirubin: 0.4 mg/dL; Magnesium: 1.7 mg/dL; CA-125: 21 U/mL; PHQ-9: 4. All results are synthetic.

## Change since baseline

- Hemoglobin: 12.4 g/dL at baseline, 10.3 g/dL (low) at this visit **S**
- White cell count: 7.8 10*3/uL at baseline, 4.1 10*3/uL at this visit **S**
- Platelets: 412 10*3/uL (high) at baseline, 188 10*3/uL at this visit **S**
- Creatinine: 0.72 mg/dL at baseline, 0.7 mg/dL at this visit **S**
- eGFR: 109 mL/min/1.73 m² at baseline, 113 mL/min/1.73 m² at this visit **S**
- ALT: 18 U/L at baseline, 24 U/L at this visit **S**
- Total bilirubin: 0.5 mg/dL at baseline, 0.4 mg/dL at this visit **S**
- CA-125: 1240 U/mL (high) at baseline, 21 U/mL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 55.9 kg; blood pressure 110/70, pulse 80 |
| Abdomen | Soft, non-tender; no fluid or mass |
| Neurological | Pinprick slightly reduced over the toes; vibration sense and ankle reflexes present; strength normal; steady gait |
| Skin | Alopecia; no rash |
| Psychiatric | Bright, engaged; organized |

All examination findings are synthetic. **S**

## Assessment and plan

1. **High-grade serous ovarian cancer, stage IIIC, on chemotherapy** (C56.3). Responding: CA-125 is normal at 21 U/mL, from 188. Counts allow cycle 4: neutrophils 1.9, platelets 188; hemoglobin 10.3 g/dL, mild anemia from chemotherapy without symptoms. Kidney and liver function are normal. Magnesium is at the lower limit (1.7 mg/dL) after three cycles of carboplatin. **S**
   - Cycle 4 today at full dose.
   - Magnesium-rich foods; recheck before each remaining cycle.
   - CT of the chest, abdomen and pelvis after cycle 6.
2. **Chemotherapy-induced peripheral neuropathy, grade 1** (G62.0). Grade 1 sensory neuropathy from paclitaxel, without functional effect. No medicine has been shown to prevent it; the dose is reduced if symptoms begin to interfere with daily activities (grade 2) or become painful. **S**
   - Continue paclitaxel at full dose with a check before each cycle.
   - Report trouble with buttons, writing, or balance, or burning pain.
   - Duloxetine if it becomes painful.
3. **Symptomatic surgical menopause** (E89.41). Hot flashes continue and she is coping with non-hormonal measures. **S**
   - Discuss hormone therapy at the end of treatment.
4. **Acute viral upper respiratory infection** (J06.9). Resolved without fever. **S**
   - No further action.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count with neutrophils and platelets | Before each chemotherapy cycle | Completed today | Hemoglobin 10.3 g/dL, white cells 4.1, neutrophils 1.9, platelets 188; cycle 4 can be given. Cycles 2 and 3 were given on schedule in the infusion center |
| Laboratory | Creatinine and estimated kidney function (carboplatin dose) | Before each cycle | Completed today | Creatinine 0.70 mg/dL, eGFR 113; carboplatin dose unchanged |
| Laboratory | Liver tests (paclitaxel) | Before each cycle | Completed today | ALT 24 U/L, bilirubin 0.4 mg/dL |
| Laboratory | Magnesium | Before each cycle | Completed today | 1.7 mg/dL, at the lower limit; dietary advice and a check before each remaining cycle |
| Laboratory | CA-125 | At diagnosis; before each cycle when raised at diagnosis; at the end of treatment; then at each surveillance visit | Deferred | 21 U/mL today, now normal. A deviation: CA-125 was not drawn before cycles 2 and 3, which were given in the infusion center with blood counts only. No harm resulted: today's value shows a response, and imaging is planned at the end of treatment. Corrective action: CA-125 at the end of treatment and at every surveillance visit; no earlier values are recorded |
| Imaging | Response imaging | At the end of primary treatment, or sooner for symptoms or a rising CA-125 | Not indicated | Not needed at the midpoint: CA-125 normal and no symptoms; CT after cycle 6 |
| Examination | Peripheral neuropathy: symptoms and examination | At baseline and before each taxane cycle | Completed today | Grade 1 sensory neuropathy; full dose continues |
| Medication safety | Nausea and vomiting control | Each cycle | Completed today | Controlled: nausea one or two days per cycle, no vomiting |
| Medication safety | Paclitaxel infusion reaction prevention | Each paclitaxel dose | Completed today | No reaction in three cycles; same premedication |
| Survey | Distress and depression screen (PHQ-9) | At diagnosis, at each treatment phase, and when symptoms change | Completed today | PHQ-9 4 |
| Self-management | Menopausal symptoms after oophorectomy | Each visit after surgery | Completed today | Hot flashes continue; managed without medicine |
| Self-management | Infection precautions and fever plan | Each cycle | Completed today | Checks her temperature after each cycle; knows to call at once for 38.0 °C or more |
| Self-management | Psychosocial support and information | At diagnosis and throughout | Completed today | Support group every other week |

## Goal progress

- Tissue diagnosis and gynecologic oncology plan within two weeks of presentation. Outcome by 1986-04-14: Ultrasound, CT and biopsy within four days; diagnosis and consultation on the eighth day. **S**
- Cytoreductive surgery with no visible residual disease within three weeks of diagnosis. Outcome by 1986-05-12: Complete gross resection one week after the diagnosis. **S**
- Six cycles of carboplatin and paclitaxel every three weeks without a delay of more than one week. In progress; target 1986-09-15. **S**
- Germline and tumor genetic results available before the maintenance decision. In progress; target 1986-09-15. **S**
- PHQ-9 below 10 throughout treatment, with a peer-support connection. In progress; target 1986-09-15. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 4.2026 (2026), National Comprehensive Cancer Network
- Salani R, et al. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 2017;146(1):3-10 (2017), Society of Gynecologic Oncology
- Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020;38(24):2782-2797 (2020), American Society of Clinical Oncology
- Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (2020), American Society of Clinical Oncology
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force
- NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections (2026), National Comprehensive Cancer Network

## Follow-up

- Cycles 5 and 6 every 21 days. CT about two weeks after cycle 6, then a review with the result and the maintenance decision. **S**
- Next scheduled visit 1986-09-15: end of chemotherapy: CT and CA-125 response, and the start of olaparib maintenance. **S**
